Low-dose aspirin for primary cardiovascular prevention in diabetic patients: the issue to believe it or not
Authors:
- 1 June 2018
- journal article
- editorial
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 6 (11) , 219
Abstract
Low-dose aspirin for primary cardiovascular prevention in diabetic patients: the issue to believe it or notKeywords
This publication has 23 references indexed in Scilit:
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEuropean Heart Journal, 2013
- Diabetes and Antiplatelet Therapy in Acute Coronary SyndromeCirculation, 2011
- Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial IndexA Randomized Controlled TrialJAMA, 2010
- Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trialsBMJ, 2009
- Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 DiabetesA Randomized Controlled TrialJAMA, 2008
- The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial diseaseBMJ, 2008
- A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in WomenNew England Journal of Medicine, 2005
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998
- Aspirin Effects on Mortality and Morbidity in Patients With Diabetes MellitusJAMA, 1992
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989